DCN and cancer: As decorin acts as a natural antagonist for IGF-IR in tumours, its decreased expression may contribute to increased IGF-IR activity, thus leading to the progression of IGF-IR-dependent cancers through enhanced cellular motility and invasion [23]–[24].